Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.) , shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment.
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
25 mg | ¥ 10,600 | 6-8周 | ||
50 mg | ¥ 13,800 | 6-8周 | ||
100 mg | ¥ 17,500 | 6-8周 |
Sitravatinib malate 的其他形式现货产品:
产品描述 | Sitravatinib malate is an orally bioavailable receptor inhibitor of tyrosine kinase (RTK) (IC50s of 1.5 nM, 2 nM, 2 nM, 5 nM, 6 nM, 6 nM, 8 nM, 0.5 nM, 29 nM, 5 nM, and 9 nM for Axl, MER, VEGFR3, VEGFR2, VEGFR1, KIT, FLT3, DDR2, DDR1, TRKA, TRKB, respectively.) , shows potent single-agent antitumor efficacy and enhances the activity of PD-1 blockade through promoting an antitumor immune microenvironment. |
靶点活性 | TrkA:5 nM, FLT3:8 nM, TrkB:9 nM, DDR2:0.5 nM, c-Kit:6 nM, DDR1:29 nM, VEGFR1:6 nM, Mer:2 nM, Axl:1.5 nM, VEGFR3:2 nM, VEGFR2:5 nM |
体外活性 | In KLN205 and E0771 cell lines,Sitravatinib (0.01 nM-10 μM; 14 days) reduces colony formation in a dose-dependent manner [2]. Sitravatinib (0.001-10 μM; 5 days) inhibits tumor cell viability(IC50s : 1 μM, in KLN205), E0771 and CT1B-A5 cell lines[2]. |
体内活性 | In C57BL/6 mice bearing CT1B-A5 cells model,Sitravatinib (20 mg/kg; p.o.; once per day for 6 days) significantly inhibits tumor progression and induces tumor regression [2]. |
别名 | MGCD516 malate, MG-516 malate |
分子量 | 763.76 |
分子式 | C37H35F2N5O9S |
CAS No. | 2244864-88-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Sitravatinib malate 2244864-88-6 Tyrosine Kinase/Adaptors TAM Receptor MG-516 Malate MGCD-516 Malate MGCD516 Malate MG516 Malate MGCD 516 Malate MG 516 Malate MGCD516 malate Sitravatinib Malate MG-516 malate Inhibitor inhibitor inhibit